These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 874095)

  • 1. Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog.
    Rutherford WE; Bordier P; Marie P; Hruska K; Harter H; Greenwalt A; Blondin J; Haddad J; Bricker N; Slatopolsky E
    J Clin Invest; 1977 Aug; 60(2):332-41. PubMed ID: 874095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of metabolic bone disease in the pre-end-stage renal disease setting.
    Coburn JW; Elangovan L
    J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S71-7. PubMed ID: 11443772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency.
    Portale AA; Booth BE; Halloran BP; Morris RC
    J Clin Invest; 1984 Jun; 73(6):1580-9. PubMed ID: 6547151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic consequences of oral administration of 24,25-dihydroxycholecalciferol to uremic dogs.
    Canterbury JM; Gavellas G; Bourgoignie JJ; Reiss E
    J Clin Invest; 1980 Mar; 65(3):571-6. PubMed ID: 7354130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease.
    Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; de Luca HF
    Proc Eur Dial Transplant Assoc; 1976; 12():227-36. PubMed ID: 935115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of low dose 1 alpha-hydroxycholecalciferol on glomerular filtration rate in moderate renal failure.
    Eke FU; Winterborn MH
    Arch Dis Child; 1983 Oct; 58(10):810-3. PubMed ID: 6357106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium metabolism in renal failure.
    David DS
    Am J Med; 1975 Jan; 58(1):48-56. PubMed ID: 1090150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between serum vitamin D metabolites and dietary intake of phosphate in patients with early renal failure.
    Tessitore N; Venturi A; Adami S; Roncari C; Rugiu C; Corgnati A; Bonucci E; Maschio G
    Miner Electrolyte Metab; 1987; 13(1):38-44. PubMed ID: 3587183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.
    Madsen S
    Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650
    [No Abstract]   [Full Text] [Related]  

  • 12. 1-alpha-hydroxyvitamin D3 in chronic renal failure. A potent analogue of the kidney hormone, 1,25-dihydroxycholecalciferol.
    Chan JC; Oldham SB; Holick MF; DeLuca HF
    JAMA; 1975 Oct; 234(1):47-52. PubMed ID: 1174223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in renal bone disease.
    Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; De Luca HF
    Calcif Tissue Res; 1976 Aug; 21 Suppl():226-35. PubMed ID: 782662
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term control of plasma calcitriol concentration in dogs and humans. Dominant role of plasma calcium concentration in experimental hyperparathyroidism.
    Hulter HN; Halloran BP; Toto RD; Peterson JC
    J Clin Invest; 1985 Aug; 76(2):695-702. PubMed ID: 3928683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium and phosphorus in diet therapy of uremia.
    Schoolwerth AC; Engle JE
    J Am Diet Assoc; 1975 May; 66(5):460-4. PubMed ID: 1123506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adult-onset vitamin D-resistant osteomalacia with the unresponsiveness to parathyroid hormone.
    Fujita T; Nomura M; Okajima S; Furuya H
    J Clin Endocrinol Metab; 1980 May; 50(5):927-31. PubMed ID: 6246136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Physiopathology of renal osteodystrophy. I. Patients with kidney failure without dialysis].
    Fournier A; Bordier P; Weil B; Safar M; Idatte JM
    Presse Med (1893); 1971 Oct; 79(45):2017-21. PubMed ID: 5119047
    [No Abstract]   [Full Text] [Related]  

  • 18. [Chronic renal insufficiency and secondary hyperparathyroidism in rats. Biochemical and histological evaluation].
    Virgós MJ; Menéndez-Rodríguez P; Serrano M; González-Carcedo A; Braga S; Cannata JB
    Rev Esp Fisiol; 1993 Dec; 49(4):241-7. PubMed ID: 8209101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of renal osteodystrophy: correlation of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone values before and after treatment with calcium carbonate or 25-hydroxycholecalciferol.
    Bordier PJ; Marie PJ; Arnaud CD
    Kidney Int Suppl; 1975 Jan; (2):102-12. PubMed ID: 1057669
    [No Abstract]   [Full Text] [Related]  

  • 20. How important is phosphate in the pathogenesis of renal osteodystrophy?
    Slatopolsky E; Rutherford WE; Hruska K; Martin K; Klahr S
    Arch Intern Med; 1978 May; 138 Spec No():848-52. PubMed ID: 646572
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.